文献速递炎症性肠病

综述:溃疡性结肠炎患者托法替布给药剂量指南

Review article: guide to tofacitinib dosing in patients with ulcerative colitis.
PubMed 文献 · Aliment Pharmacol Ther · 2022-08-22

托法替布是治疗溃疡性结肠炎的口服小分子Janus激酶抑制剂,诱导剂量为10 mg每日两次,维持治疗应使用最低有效剂量。本文基于托法替布溃疡性结肠炎临床项目数据及真实世界数据,结合专家意见,探讨5 mg或10 mg每日两次的剂量调整策略及临床考量。

要点

  • 托法替布诱导剂量为10 mg每日两次,维持治疗应使用最低有效剂量。
  • 调整剂量需考虑疾病严重程度、合并症和既往生物制剂暴露。
  • 减量或中断治疗后应密切监测疾病复发,以便早期重新捕获应答。

核心结论

  • 临床医生必须权衡托法替布10 mg与5 mg每日两次在剂量相关副作用方面的获益/风险平衡,以及治疗活动性疾病不足的安全性影响。
  • 所有患者在减量或中断治疗后应密切监测疾病复发,以便早期重新捕获应答。

研究设计与样本

  • 综述文章,基于托法替布溃疡性结肠炎临床项目数据在不同临床场景下评估托法替布5 mg或10 mg每日两次的使用,并纳入专家关于剂量调整临床意义的意见及真实世界数据。

主要发现

  • 调整托法替布剂量时需要考虑的因素包括疾病严重程度、合并症和既往生物制剂暴露。
  • 内镜子评分可判断患者是否是减量的良好候选者。
  • 疾病复发后,通过增加剂量可在相当数量的患者中重新捕获应答。
  • 已发表的真实世界使用数据迄今与临床试验数据一致。

临床怎么用

  • 临床医生必须考虑托法替布10 mg与5 mg每日两次在剂量相关副作用方面的获益/风险平衡,以及治疗活动性疾病不足的安全性影响。
  • 所有患者在减量或中断治疗后应密切监测疾病复发,以便早期重新捕获应答。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). The induction dose is 10 mg twice daily (b.d.), whilst for maintenance therapy, the lowest effective dose should be used. AIM: To examine published evidence on the two tofacitinib dosing strategies used in UC treatment, including expert interpretation of the data and how they could inform clinical practice. METHODS: The use of tofacitinib 5 or 10 mg b.d. was assessed using data from the tofacitinib UC clinical programme in the context of different clinical scenarios. We include experts' opinions on the clinical implications of dose adjustment to inform the benefit/risk of using tofacitinib 5 or 10 mg b.d., based on clinical scenarios and real-world data. RESULTS: Factors to consider when adjusting the tofacitinib dose include disease severity, comorbidities and previous biological exposure. The endoscopic subscore can determine whether a patient is a good candidate for dose reduction. Following disease relapse, the response can be recaptured in a substantial number of patients with a dose increase. Furthermore, data are now published showing real-world use of tofacitinib and, so far, these are consistent with data from the clinical trials. CONCLUSION: Clinicians must consider the benefit/risk balance of tofacitinib 10 versus 5 mg b.d. in terms of dose-related side effects, as well as the safety implications of undertreating active disease. All patients should be closely monitored for disease relapse following dose reduction or interruption for early recapture of response. Guide to tofacitinib dosing in patients with ulcerative colitis.[Image: see text]

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Irving PM, Leung Y, Dubinsky MC, et al. Review article: guide to tofacitinib dosing in patients with ulcerative colitis. Aliment Pharmacol Ther. 2022. PMID: 35993338. doi:10.1111/apt.17185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。